Current News

05/08/13: Raptor Pharmaceutical Reports First Quarter Calendar Year 2013 Financial Results

05/07/13: Raptor Pharmaceutical Licenses Intellectual Property for Rett Syndrome From French Research Institutes

05/01/13: Multimedia Now Available: Raptor Pharmaceutical's PROCYSBI™ Receives FDA Approval

04/30/13: Raptor Pharmaceutical's PROCYSBI™ Receives FDA Approval

Raptor’s mission is to develop and commercialize life-altering therapeutics that treat debilitating and often fatal diseases.

The Company anticipates receiving a determination from the EMA regarding its PROCYSBI™ marketing application in the European Union in the second half of 2013.